 SOUTH SAN FRANCISCO, Calif., April 7, 2021 PRNewswire -- Rigel Pharmaceuticals, Inc. Nasdaq: RIGL today announced the successful closing of its license agreement with Eli Lilly and Company Lilly, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. 